ABSTRACT
Mycosis fungoides (MF) is the most prevalent subtype of primary cutaneous T-cell lymphomas (CTCLs). Sézary syndrome (SS) is another entity defined by leukaemic involvement, lymphadenopathy and erythroderma. Pegylated liposomal doxorubicin (PEG-DOXO) is an anthracycline used in the management of advanced primary CTCL, particularly in induction strategies. However, there are limited data on its effectiveness and tolerability in real-life patients. We report 36 patients who received PEG-DOXO for MF or SS in our centre, describing the patients' characteristics, response rates and tolerance to the treatment. The best overall responses were observed for the skin, with lower response rates for nodal involvement and moderate responses for blood disease. The treatment was mainly well tolerated, without severe adverse events, and no cardiotoxicity was observed on cardiac function monitoring.
Subject(s)
Lymphoma, T-Cell, Cutaneous , Mycosis Fungoides , Sezary Syndrome , Skin Neoplasms , Doxorubicin/adverse effects , Doxorubicin/analogs & derivatives , Humans , Lymphoma, T-Cell, Cutaneous/pathology , Mycosis Fungoides/drug therapy , Mycosis Fungoides/pathology , Polyethylene Glycols , Sezary Syndrome/drug therapy , Sezary Syndrome/pathology , Skin Neoplasms/pathologyABSTRACT
Bullous pemphigoid (BP) is an acquired autoimmune bullous disease characterized by autoantibodies against the hemidesmosomal proteins found in the basal keratinocytes of the basement membrane zone (BMZ): a 180 kDa protein (type XVII collagen) mainly and the 230 kDa antigen. There is such evidence that the antibodies against the BMZ components are not only of IgG type, but also this bullous disease may have IgE antibodies directed to the BMZ that contribute to the pathogenesis of the disorder. IgE is not only thought to contribute to the pathogenesis of BP, it has also been suggested that eosinophils play a role in the development of the first signs associated with BP. A humanized monoclonal antibody directed to IgE, omalizumab, is approved for the treatment of severe asthma and chronic spontaneous urticaria, and it may be useful in the treatment of BP in the first stages of the disease.
Subject(s)
Autoantibodies/immunology , Omalizumab/therapeutic use , Pemphigoid, Bullous/drug therapy , Aged, 80 and over , Female , Humans , Immunoglobulin E/immunology , Omalizumab/pharmacology , Pemphigoid, Bullous/immunologySubject(s)
Acne Vulgaris , Hyperostosis , Osteitis , Synovitis , Acne Vulgaris/diagnosis , Acne Vulgaris/drug therapy , Humans , SyndromeSubject(s)
Lentigo , Leukemia-Lymphoma, Adult T-Cell , Lymphoma, T-Cell, Cutaneous , Skin Neoplasms , Humans , Lymphoma, T-Cell, Cutaneous/chemically induced , Lymphoma, T-Cell, Cutaneous/diagnosis , Lymphoma, T-Cell, Cutaneous/drug therapy , Antibodies, Monoclonal, Humanized/adverse effects , Skin Neoplasms/chemically induced , Skin Neoplasms/diagnosis , Skin Neoplasms/drug therapy , Leukemia-Lymphoma, Adult T-Cell/pathologySubject(s)
Adjuvants, Immunologic/adverse effects , Cocaine/adverse effects , Levamisole/adverse effects , Purpura/diagnosis , Vasculitis/diagnosis , Vasoconstrictor Agents/adverse effects , Cocaine-Related Disorders/complications , Female , Humans , Middle Aged , Purpura/etiology , Vasculitis/etiologySubject(s)
Antiviral Agents/adverse effects , Betacoronavirus , Coronavirus Infections/complications , Erythema Multiforme/etiology , Pandemics , Pneumonia, Viral/complications , Aged, 80 and over , Anti-Inflammatory Agents/therapeutic use , Antiviral Agents/therapeutic use , COVID-19 , Causality , Coronavirus Infections/drug therapy , Drug Eruptions/drug therapy , Drug Eruptions/etiology , Erythema Multiforme/chemically induced , Erythema Multiforme/drug therapy , Humans , Male , Middle Aged , Pneumonia, Viral/drug therapy , Prednisone/therapeutic use , SARS-CoV-2 , COVID-19 Drug TreatmentSubject(s)
Betacoronavirus/pathogenicity , Coronavirus Infections/complications , Exanthema/etiology , Pneumonia, Viral/complications , Adult , Betacoronavirus/isolation & purification , COVID-19 , Coronavirus Infections/diagnosis , Cough/etiology , Exanthema/virology , Female , Fever/etiology , Humans , Nasopharynx/virology , Pandemics , Pneumonia, Viral/diagnosis , SARS-CoV-2Subject(s)
Betacoronavirus , Coronavirus Infections/complications , Coronavirus Infections/diagnosis , Pneumonia, Viral/complications , Pneumonia, Viral/diagnosis , Urticaria/pathology , Urticaria/virology , Acute Disease , COVID-19 , Coronavirus Infections/therapy , Female , Humans , Middle Aged , Pandemics , Pneumonia, Viral/therapy , SARS-CoV-2 , Urticaria/therapySubject(s)
Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy , Psoriasis/drug therapy , Thalidomide/analogs & derivatives , Humans , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/complications , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/diagnosis , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/immunology , Male , Middle Aged , Psoriasis/complications , Psoriasis/diagnosis , Psoriasis/immunology , Severity of Illness Index , Thalidomide/therapeutic use , Treatment OutcomeSubject(s)
Alopecia/chemically induced , Biological Products/adverse effects , Certolizumab Pegol/adverse effects , Psoriasis/chemically induced , Sacroiliitis/drug therapy , Alopecia/diagnosis , Alopecia/pathology , Biological Products/administration & dosage , Biopsy , Certolizumab Pegol/administration & dosage , Drug Substitution , Female , Humans , Middle Aged , Psoriasis/diagnosis , Psoriasis/pathology , Skin/drug effects , Skin/pathology , Ustekinumab/administration & dosageABSTRACT
No disponible
Subject(s)
Humans , Male , Middle Aged , Aged, 80 and over , Erythema Multiforme/complications , Coronavirus Infections/complications , Erythema Multiforme/diagnosis , Erythema Multiforme/therapy , Skin Diseases/physiopathologyABSTRACT
No disponible